{"url_path":"/sec/lrmr/8-k/2026-05-14/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1374690/0001193125-26-222746-index.html","accession_number":"0001193125-26-222746","cik":"0001374690","ticker":"LRMR","issuer_name":"Larimar Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1374690/0001193125-26-222746-index.html","primary_entity_key":"0001374690","primary_entity_name":"Larimar Therapeutics, Inc."},"word_count":141,"has_tables":true,"body_markdown":"## Item 2.02 Results of Operations and Financial Condition.\n\nOn May 14, 2026, Larimar Therapeutics, Inc. (the “Company”) announced its financial results and operational highlights for the first quarter ended March 31, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\nThe information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing."}